ERBB2 and breast cancer: In MINADCT study (21% N1 and 79% node negative respectively), 49% patients of HR+/HER2‐ breast cancer were low risk by both of clinical and genomic results, and additionally 46% patients with high clinic risk were low risk by Mammaprint who could omit chemotherapy at the very beginning.27